Evidence map›Paper›PMID 41907374›Full record

ReviewInternational journal of nanomedicine2026

Novel Strategies for Precision Diagnosis and Treatment of Prostate Cancer Based on Multifunctional Nanocarrier Systems.

Zhonghao Tang, Si Shen, Chenwei Gu, Sixin Li, Jiang Ni, Dongjie Yang, Yuanyuan Mi

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhonghao Tang *Department of Urology, Affiliated Hospital of Jiangnan University, Wuxi, People's Republic of China.
Si Shen *Department of Urology, Affiliated Hospital of Jiangnan University, Wuxi, People's Republic of China.
Chenwei Gu *Department of Urology, Affiliated Hospital of Jiangnan University, Wuxi, People's Republic of China.
Sixin Li *Department of Urology, Affiliated Hospital of Jiangnan University, Wuxi, People's Republic of China.
Jiang Ni *Department of Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi, People's Republic of China.
Dongjie YangDepartment of Pathology, Affiliated Hospital of Jiangnan University, Wuxi, People's Republic of China.
Yuanyuan MiDepartment of Urology, Affiliated Hospital of Jiangnan University, Wuxi, People's Republic of China.ORCID 0000-0003-3456-523X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer (PCa) is one of the most common malignancies in men worldwide, and its current diagnostic and therapeutic methods still face severe challenges in terms of specificity, efficacy, and toxicity. The emergence of nanotechnology provides a powerful platform to overcome these obstacles. Through the design of sophisticated nanocarriers, targeted delivery and controlled release of therapeutic agents, as well as the synergy of multiple treatment modalities, can be achieved, thereby significantly improving efficacy and reducing side effects. Meanwhile, nanotechnology shows great potential in developing highly sensitive diagnostic tools and theranostic platforms, laying the foundation for early detection and precise treatment of PCa. Although challenges such as scalability and safety remain to be addressed before clinical translation, nanotechnology is undoubtedly reshaping the landscape of PCa management and driving the field towards personalized medicine. This review aims to provide a systematic overview of significant advancements in nanotechnology for the diagnosis and treatment of PCa over the past three years. It focuses on innovative research in novel nanocarrier design, targeting strategies, and the construction of integrated diagnostic and therapeutic platforms. Furthermore, current challenges and future directions for clinical translation are discussed, with the aim of offering valuable insights and references for researchers and clinicians in this field.

Indexed as

Multifunctional NanoparticlesPrecision MedicineProstatic NeoplasmsAnimalsAntineoplastic AgentsHumansMaleTheranostic NanomedicineAntineoplastic Agentsnanocarriersprostate cancertargeted deliverytheranostics

Identifiers

PMID41907374
PMCPMC13017186

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.